Priya Singhal, MD, MPH, who leads Development at Biogen, sat down with Mary Civiello, to share more about how Biogen is building on a strong legacy to pursue breakthrough medicines for the future.

At the heart of Biogen’s transformation is a pipeline of innovative medicines. After decades leading in neurology, we’re evolving and diversifying our pipeline and homing in on where we think we can make the biggest difference in neurology, immunology, and rare disease.

These areas of focus are not new territory for Biogen. “We’re building on our roots, maintaining the spirit of our Nobel laureate founders in 1978 who wanted to go after hard-to-treat diseases,” explains Priya. “We’re now taking a more balanced approach, diversifying our pipeline, allocating our resources where we can have the greatest impact, and keeping patients and stakeholders at the center of every decision. Our end goal is to drive sustainable growth and to continue bringing innovative medicines to patients who need them most.”

Now we’re expanding, and we’re moving faster. While we diversify our clinical portfolio, we’ve also introduced a new “open innovation” model for preclinical research. We expect this approach will position us to continue delivering therapies that patients need, while building a stronger pipeline for the future.

Watch below to hear Priya lay out Biogen’s path forward.